top of page

Nucleus Presents Top Psychedelics CEOs During Psychedelic Series at Soho Beach House Miami

Nucleus, a venture studio for psychedelics wholly owned by Iter Investments, will present its monthly Psychedelic Series at Soho Beach House Miami on Thursday, July 20, at 7 p.m. Moderated by psychedelics expert Dustin Robinson, Esq. CPA., the panel will feature top CEOs in the psychedelics industry including PsyBio Therapeutics CEO Evan Levine and Braxia Scientific CEO Dr. Roger McIntyre. The topic of the panel will focus on the next wave of psychedelic medicine.

Levine is an assertive and insightful leader encompassing over three decades of in-depth expertise in biotechnology and drug development, executive supervision, strategic ventures, asset management and the institutional investment business. He is currently chairman and CEO of PsyBio Therapeutics, a neuropsychiatry drug development company pioneering the next generation of psychoactive compounds. The company has a platform technology that can produce biosynthetically generated psychoactive drugs utilizing genetically modified bacteria. Levine was responsible for co-founding the company, acquiring key platform technology, funding an institutional round led by US venerated healthcare funds, and taking the company public on the Toronto Venture Exchange.

Dr. McIntyre is the chairman and CEO of Braxia Scientific, a medical research and telemedicine company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Dr. McIntyre is the world’s top-ranked depression researcher and has almost 25 years of providing care and conducting research, along with drug discovery and development, for persons with depression and related disorders. He is currently also a professor of psychiatry and pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto, Canada. Under his leadership, Braxia also launched its U.S.-based end-to-end telemedicine platform KetaMD, which utilizes leading technology to provide access to safe, affordable, and potentially life-changing at-home ketamine treatments for people living with depression and related mental health conditions. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others.

Robinson is Founding Partner of Mr. Cannabis Law – a full service law firm focused on the cannabis and psychedelic industries; Co-Founder of Mr. Psychedelic Law – a non-profit focused on psychedelic legal reform; Managing Principal of Iter Investments – a venture capital firm deploying capital across the psychedelic ecosystem; and Co-Founder of Nucleus – a platform with various tools to help guide individuals on their mental health journey.

Launched in June 2021 by Robinson and visionary leader Sam Baum, the Psychedelic Series features experts in the psychedelics space including CEOs, doctors, lawyers and celebrities. The panel started at Soho Beach House Miami and expanded to locations throughout the country including New York, Chicago and California, as well as internationally in London and Amsterdam. Past panelists include MAPS Founder Rick Doblin, NBA champion Lamar Odom, Psilera Bioscience CEO Chris Witowski, PhD, Silo Wellness CEO Douglas K. Gordon, and others.

The event is private and only open to Soho House members.


Thursday, July 20; 7 p.m. ET


Soho Beach House Miami

4385 Collins Ave., Miami Beach, FL 33140

By ML Staff. Images by Nucleus. Top image by Unsplash


bottom of page